Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1161-1180 of 2,120 trials

Glucothera Plus for Children on Peritoneal Dialysis

We are studying the safety of Glucothera Plus in children receiving peritoneal dialysis. We also want to see if it helps restore L-carnitine levels in these patients.

End-stage Kidney Disease6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNephrologyPediatrics

CNS Lymphoma: [90Y]Y-PentixaTher Therapy

We are studying the safety and effectiveness of [90Y]Y-PentixaTher in patients with recurrent or refractory central nervous system lymphoma. This trial aims to find the best dose and understand how the treatment works in the body.

CNS LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Pain Management After Colorectal Surgery: Continuous Wound Infusion Study

We are investigating whether continuous infusion of local pain relief helps patients recover better after minimally invasive colorectal surgery. The study compares this method to a placebo to see its effects on pain and recovery time.

Recovery After Colorectal Surgery1-2 yearsConfirmation phase (III)Standard MedicinesGastroenterologyInternal MedicineOtolaryngology

Brain Surgery Pain Management: Nerve Block Comparison

We are comparing two types of nerve blocks to see which one helps reduce pain and improve recovery for patients undergoing brain surgery. This study aims to find the best option for managing discomfort during the procedure.

Patients Undergoing Craniotomy for Supratentorial Mass>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Severe Asthma: Tezepelumab Medication Study

We are studying if tezepelumab can help patients aged 12 to 80 with severe asthma reduce their daily medication while keeping their symptoms under control.

Severe Asthma1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePulmonology

Colorectal Cancer: Encorafenib and Cetuximab with Pembrolizumab

We are studying a combination of medications for patients with BRAF V600E-mutant metastatic colorectal cancer. The goal is to see if this combination works better than pembrolizumab alone.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Prostate Cancer: Darolutamide Addition Study

We are studying whether adding darolutamide to standard treatment helps men with metastatic castration-resistant prostate cancer live longer without cancer progression.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Multiple Myeloma: Etentamig and Iberdomide Study

We are investigating the safety and effects of a new treatment combining etentamig and iberdomide for patients with relapsed or refractory multiple myeloma. This study aims to find the best doses and assess how well the treatment works.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

GLM101 for PMM2-CDG: Safety and Effects

We are studying the safety of GLM101 in patients with PMM2-CDG who have previously received the treatment. We will also look at its impact on coordination, balance, and sugar levels.

PMM2-CDGEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal Medicine

Advanced Non-Small Cell Lung Cancer: PD-1 Inhibitor with Chemotherapy and Radiation

We are studying whether adding radiation to a PD-1 inhibitor and chemotherapy improves survival and tumor response in patients with advanced non-small cell lung cancer. This trial also looks at side effects and quality of life.

Advanced Non-Small Cell Lung Cancer (NSCLC)3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Metastatic Colorectal Cancer: Post-Surgery Chemotherapy Study

We are investigating whether adding chemotherapy after surgery or ablation helps improve outcomes for patients with metastatic colorectal cancer compared to just follow-up care.

Metastatic Colorectal CancerConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Bladder Cancer: Nadofaragene Firadenovec Treatment

We are studying the safety and effectiveness of nadofaragene firadenovec, given alone or with chemotherapy or immunotherapy, for adults with non-muscle invasive bladder cancer that hasn't responded to BCG therapy.

High-risk Non-Muscle-Invasive Bladder Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Fluid Overload in ICU: Furosemide Treatment

We are studying whether a diuretic called furosemide helps critically ill patients with fluid overload recover better than a placebo. The focus is on increasing the number of days alive and out of the hospital after 90 days.

Fluid Overload>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

Distal Radius Fracture: Brachial Plexus Nerve Block

We are studying whether an ultrasound-guided nerve block helps adults with distal radius fractures manage pain better than standard treatment during closed reduction. This trial will assess both the benefits and potential risks.

Distal Radius Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOrthopedics and Traumatology

Futibatinib Safety Study for Cancer Patients

We are collecting long-term safety information for patients who previously benefited from futibatinib treatment. This study helps ensure that continuing the medication remains safe for them.

Malignant Solid Tumors1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Metastatic Melanoma: Early Detection of Side Effects

We are investigating whether a special imaging technique can help identify early side effects in patients receiving immune therapy for metastatic melanoma. This study aims to improve monitoring of immune-related side effects.

Malignant Melanoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ependymoma Treatment: SIOP Ependymoma II Program

We are exploring new chemotherapy options and surgical techniques for children and young adults with ependymoma. Our goal is to improve survival rates and treatment effectiveness compared to standard methods.

Ependymoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Small Cell Lung Cancer: Durvalumab Immunotherapy

We are studying whether durvalumab can help frail patients with limited small cell lung cancer live longer without disease progression after receiving thoracic chemoradiotherapy. The trial also examines the treatment's safety and its effects on quality of life.

Limited Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Takayasu Arteritis: Infliximab vs. Tocilizumab

We are studying whether Infliximab is more effective than Tocilizumab for patients with refractory or relapsing Takayasu arteritis. The goal is to see if it helps reduce disease activity and steroid use.

Takayasu's Arteritis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyRheumatology

Primary Hyperoxaluria: DCR-PHXC Injection Study

We are evaluating a new injection for patients with Primary Hyperoxaluria to see how it affects kidney function and overall safety. The study also looks at its impact on kidney stones and quality of life.

Primary Hyperoxaluria>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNephrology